Last updated on May 2016

DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma


Brief description of study

Evaluation of DC-CIK cells combined TACE treatment for HCC

Detailed Study Description

60 patients with Hepatocellular Carcinoma, who had received Transcatheter Arterial Chemoembolization (TACE) , will be randomly divided into group A (receive DC-CIK+ TACE treatment) or group B (just receive TACE), and the randomize ratio will be 1:1.

Clinical Study Identifier: NCT02487017

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Xiangzhong Liu, Professor

Yantai City Hospital for Infectious Diseases
Yantai, China
  Connect »